- Home
- RARE vs ALRM Comparison
RARE vs ALRM Comparison
Compare RARE & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ALRM
- Stock Information
- Founded
- RARE 2010
- ALRM 2000
- Country
- RARE United States
- ALRM United States
- Employees
- RARE N/A
- ALRM N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ALRM Computer Software: Prepackaged Software
- Sector
- RARE Health Care
- ALRM Technology
- Exchange
- RARE Nasdaq
- ALRM Nasdaq
- Market Cap
- RARE 3.1B
- ALRM 2.8B
- IPO Year
- RARE 2014
- ALRM 2015
- Fundamental
- Price
- RARE $33.28
- ALRM $51.22
- Analyst Decision
- RARE Strong Buy
- ALRM Buy
- Analyst Count
- RARE 13
- ALRM 5
- Target Price
- RARE $87.69
- ALRM $62.60
- AVG Volume (30 Days)
- RARE 1.5M
- ALRM 389.6K
- Earning Date
- RARE 11-03-2025
- ALRM 11-06-2025
- Dividend Yield
- RARE N/A
- ALRM N/A
- EPS Growth
- RARE N/A
- ALRM 17.96
- EPS
- RARE N/A
- ALRM 2.37
- Revenue
- RARE $610,159,000.00
- ALRM $975,867,000.00
- Revenue This Year
- RARE $19.72
- ALRM $7.89
- Revenue Next Year
- RARE $23.29
- ALRM $4.24
- P/E Ratio
- RARE N/A
- ALRM $21.59
- Revenue Growth
- RARE 26.77
- ALRM 7.81
- 52 Week Low
- RARE $25.81
- ALRM $48.23
- 52 Week High
- RARE $56.38
- ALRM $70.06
- Technical
- Relative Strength Index (RSI)
- RARE 58.42
- ALRM 44.49
- Support Level
- RARE $32.40
- ALRM $49.70
- Resistance Level
- RARE $34.78
- ALRM $51.19
- Average True Range (ATR)
- RARE 1.26
- ALRM 1.18
- MACD
- RARE 0.27
- ALRM 0.14
- Stochastic Oscillator
- RARE 71.21
- ALRM 56.94
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ALRM Alarm.com Holdings Inc.
Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices.